LOKELMATM▼ Sodium Zirconium Cyclosilicate
SWIFT* K+ REDUCTION AFTER ONE HOUR.1,2
SUSTAINED K+ CONTROL FOR UP TO ONE YEAR
WHEN USED AS A MAINTENANCE THERAPY.†1
NOW IN YOUR HANDS.
New, highly-selective LOKELMA (sodium zirconium cyclosilicate)
is indicated for the treatment of hyperkalaemia in adult patients1
*In an emergency situation, standard of care should be used in line with local or national guidelines
†Clinical trials with LOKELMA have not included exposure longer than one year
HARMONIZE Extension Phase
Sustained K+ control for up to 1 year when used as maintenance therapy*1
- 88% patients in the extension phase, who were receiving LOKELMA, maintained an average
serum K+ of 5.1 mmol/L over 11 months1
*Clinical trials with LOKELMA have not included exposure longer than 1 year1
Mean serum K+ levels across correction, maintenance and extension phases†1
Adapted from Kosiborod M, et al. JAMA. 2014;312(21):2223-2233 and LOKELMA SmPC 2018.
†Primary endpoint: mean serum K+ level with LOKELMA vs placebo on days 8–29. Eligible patients then continued treatment with LOKELMA 10 g once daily, which could be titrated to 5 g or 15 g, in an 11-month, open-label extension study (ZS004E). Please note that LOKELMA 15 g is not approved for use.1,2,23
‡Please note that the recommended starting dose for maintenance therapy with LOKELMA is 5 g once daily, which may be titrated to 10 g once daily as needed. No more than 10 g once daily should be used for maintenance therapy.
The 5 g once-daily dose can be down titrated to 5 g every other day.1
Significant reductions in mean serum K+ during days 8–29 was shown with LOKELMA vs placebo (p<0.001)2
- 4.8 mmol/L with LOKELMA 5 g (95% CI, 4.6–4.9)
- 4.5 mmol/L with LOKELMA 10 g (95% CI, 4.4–4.6)
- 5.1 mmol/L with placebo (95% CI, 5.0–5.2)